LY4175408

Phase 1Small molecule

Eli Lilly

LY4175408 is one of 48 small molecule programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungRecruiting

Carcinoma, Non-Small-Cell LungPhase 1

Recruiting

Competition

Competitive Landscape

56 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Rybrevant

Johnson & Johnson

Phase 3

11 2

Keytruda

Merck & Co.

Phase 3

10 3

Lazcluze

Johnson & Johnson

Phase 3

7 4

Imfinzi

AstraZeneca

Phase 3

4 5

Taxol

Teva

Phase 3

3 6

Paraplatin

AAvyxa

Phase 3

12 7

Tagrisso

AstraZeneca

Phase 3

2 8

Alimta

GGynecologic Oncology Group

Phase 3

10 9

Gemzar

Johnson & Johnson

Phase 3

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07046923

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07046923·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4175408. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4175408 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4175408. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4175408

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News